In Burkitt's lymphoma (BL) cells due to a t(8;14) chromosomal translocation c-myc is often placed in proximity to the Em enhancer of the Ig locus and upregulated. We demonstrated that in BL cells a peptide nucleic acid (PNA), complementary to intronic Em sequences (PNAEmwt), specifically blocks the expression of the c-myc oncogene under the Em enhancer control and inhibits BL cell growth in culture. Here, we investigated whether PNAEmwt was also able to block tumor growth in SCID mice inoculated with human BL cell lines. After subcutaneous inoculum in mice BL cells reproducibly form tumors. Both pre-treatment of BL cells with PNAEmwt before inoculum and chronic intravenous administration of PNAEmwt to mice already inoculated with BL cells selectively caused increased latency of tumor appearance and decreased final tumor size. Tumors from PNAEmwt-treated animals showed substantial areas of cell necrosis and of c-myc downregulation. Inhibition of tumor growth was specific and was not observed with PNAEmmut carrying sequence mutations and in BL cell lines where the translocated c-myc is not under the control of the Em enhancer. These data confirm the potential therapeutic value of PNA targeted to regulatory non-coding regions.
Introduction
Peptide nucleic acids (PNAs) are nucleic acid analogs where the natural backbone is substituted with uncharged pseudo peptidic 2-aminoethyl glycine units. 1 They are resistant to nucleases and proteases and bind with high affinity and specificity to complementary RNA and DNA. Moreover, PNAs can invade duplex DNA and hybridize with complementary sequences successfully displacing the natural cDNA strand. 1 In previous in vitro studies, we have shown that problems related to poor access of naked PNAs to the cell nucleus could be overcome by linking PNAs to a nuclear localization signal (NLS). 2 PNAs linked to the appropriate NLS have been recently used to selectively inhibit the expression of specific genes. In Burkitt's lymphoma (BL) c-myc is generally upregulated following its translocation from chromosome 8 to chromosome 14 (or more rarely chromosome 2 or 22) where it is juxtaposed to one of the Ig chain loci.
3 c-myc expression can be downregulated by targeting the c-myc gene itself with a specific complementary PNA. The PNA used in our laboratory binds to a unique c-myc sequence located in the second exon (PNAmyc). 2 Alternatively, we have targeted the Em enhancer of the IgH chain locus on chromosome 14 with a specific complementary PNA (PNAEmwt). This strategy was suggested by the observation that, in a large portion of BL, a t(8;14) translocation brings the c-myc oncogene in proximity of the Em enhancer sequence which consequently becomes responsible of c-myc overexpression. A block of the Em caused by PNA should result in a selective downregulation of the translocated c-myc. The use of PNAEmwt has two potential advantages: first it downregulates only the translocated oncogene, thus reducing the potential toxic effect of PNAs targeted to coding sequences that hinder transcription of both translocated and non-translocated alleles, 4 second the specificity of the inhibition can be monitored using BL cell lines (like BRG) where the translocated c-myc is under the control of Em or BL cells (like Ramos) where c-myc is translocated near the switch (S) m region outside the control of the Em enhancer.
Indeed, comparative studies in BRG-and Ramos-BL cells using PNAmyc and PNAEm demonstrated that these two reagents have the same capacity of specifically inhibit cmyc expression and that PNAEm selectively inhibited only the c-myc under Em control.
BL cells reproducibly grow in SCID mice. Using this animal model system, 5 it was possible to evaluate PNAEm toxicity as well as distribution and persistence in normal and neoplastic tissues. In these studies, toxicity was never observed following PNAs administration. However, a persistence of the therapeutically active portion of the PNAEm was demonstrated in all analyzed tissues and particularly within BRG cells derived tumors. 5 The concentration of PNAEm in these tumors in vivo, even several hours after administration to the mice, was high enough to theoretically inhibit BL cells growth at least based on the concentrations calculated in the course of our in vitro studies. 4 As consequence of the above summarized results, we here investigated the actual capacity of PNAEm to inhibit BL cells growth in SCID mice. The subcutaneous (s.c.) inoculation mode was selected for BL cells since it resulted in the growth of palpable and eventually measurable masses. PNAEm pretreatment of BRG-BL cells successfully inhibited tumor growth in vivo. Moreover, reduction of newly formed BRG-BL-derived tumor masses was observed as consequence of the administration of PNAEm to the SCID mice bearing BL tumors.
Materials and methods

PNA synthesis
PNAs were manually synthesized under license of PerSeptive Biosystem using solid-phase peptide synthesis by Boc chemistry. First, the peptidic NLS (PKKKRKV) was synthesized followed by the PNA sequence portion. All compounds were purified by reverse phase highperformance chromatography on a Shimadzu LC-9A preparative high-performance chromatography equipped with a phenomenex C18 Luna column (21.20 ID Â 250 mm length). Mass spectra of each compound were obtained in the positive ion mode using an ion trap mass spectrometer (MSD 1100 -Agilent Technologies, Palo Alto, CA, USA) equipped with an electro spray ion source. 2 The PNA oligomers used in this study were PNAEmwt GCAGGAAGCAGGTCACCG-NLS [GenBank accession no. X00253.1, bases 136-157] PNAEmmut GTAGGAAGTAGGTCATCG-NLS. 4 Cell culture and treatments Two BL cell lines (BRG 6 and Ramos 7 ) were used and kept in culture as previously described 3 in RPMI 1640 medium (Seromed-Biochrom KG, Berlin, D) supplemented with 10% fetal bovine serum (FBS) (Seromed), 1% glutamine, 1% Na piruvate and 2% penicillin-streptomycin.
Cells pre-treated before inoculation were carried out for 8 h by addition of PNAs (stock solution 1 mM in H 2 O) directly to the culture medium to a 10 mM final concentration. Cells were then centrifuged and resuspended in medium (1.5 Â 10 6 /100 ml). PNAEm tumors 'cure'. Groups of six female SCID mice per experiment were injected s.c with BRG (exactly as above).
In each experiment one group of mice was left untreated (control). Two other matching mice groups, 10 days after inoculum, were injected i.v. every other day with 100 ml of 0.2mM PNAEmwt and PNAEmmut, respectively. All mice were monitored for weight variation and tumor appearance/size at every injection time.
Tumor volume was calculated from the measurement in mm 3 as (V ¼ 0.523 Â length in mm Â width 2 in mm 2 ).
Tumor cells recovery and characterization
At the end of the experiment tumor bearing mice were killed in a saturated CO 2 chamber and autopsies were performed. Subcutaneous tumors, well-defined and non-metastatic, were isolated and placed quickly in medium in sterile conditions or fixed in formalin.
Cell surface/cytoplasmic markers. Tumor cells were mechanically gently resuspended, freed from tissue debris and clumps in culture medium and stained with the following mAbs 6 (Becton Dickinson, Sunnybay, CA, USA) specific for: CD19, m chain, k and l light chains, and for the T lymphocytes specific marker CD8 as negative control. These reagents were used in indirect immunofluorescence with a goat anti-mouse Ig antibody. In the case of m, k or l molecules both surface and intracytoplasmic staining on permeabilized cells was carried out. Staining for MYC protein was also performed (clone 9E10; Calbiochem, San Diego, CA, USA) on permeabilized cells and analyzed by flow cytometry using a FACStar analyzer (Becton Dickinson). 4 Control preparations consisted of unstained cells, cells stained with the FITC-labeled second reagent alone, and cells treated with an unrelated Ab followed by the FITC-labeled second reagent.
c-myc gene transcription and translation. Transcription of c-myc and IgM mRNA was evaluated by Northern blot as previously described.
2,4 MYC and IgM cellular level was determined by Western blot as already reported 2, 4 both in BL cells pre-treated with PNAs before inoculum and in cells from tumors of chronically PNAEmwt-treated mice after the inoculum with BL.
Morphological and immunohistochemical analysis
Subcutaneous tumor masses (from mice) were removed, fixed in formalin and embedded in paraffin. Paraffinembedded tissues were sectioned at 4 mm, mounted on charged slides, de-paraffinized in xylene and re-hydrated through graded alcohols.
Cells morphology was evaluated by microscope analysis after hematoxylin and eosin staining.
Immunohistochemical analysis was performed using 9E11 Clone of NCL-cMYC mouse monoclonal antibodies for Human c-myc oncoprotein (Novocastra, Newcastle, UK). The antigene was localized by means of a Ventana Medical System/viewt DAB detection Kit (Ventana Medical Systems, S.A Strasbourg, France). Immunostaining was performed using an automated immunostainer NEX ES (Ventana Medical Systems) programmed for antigen retrieval. Finally, the sections were counterstained with hematoxylin. Negative controls were obtained by omitting the primary antibody.
Statistical analysis
Statistical analysis of the data was performed with SPSS 11.5. base for Windows.
Results
Specific inhibition of BRG-BL cells growth in SCID mice by pre-treatment with PNAEmwt
In these experiments, we investigated whether pre-treatment of BL cells with PNAEmwt in vitro could result in their growth inhibition in SCID mice.
Two cell lines were used: -BRG where the enhancement of the c-myc oncogene expression was under the Em enhancer control and -Ramos where Em was deleted from chromosome 14 and the translocated c-myc was located in proximity of the Sm region, away from Em control. 8 Besides PNAEmwt, designed to specifically bind Em, a PNA unable to bind Em because of three evenly spaced base mutations in the sequence (PNAEmmut) was designed as negative control. When 1.5 Â 10 6 BRG cells (either untreated or treated with PNAEmmut) were inoculated s.c. in six SCID mice, tumor masses were detectable before the day 18 after inoculum and measurable at the day 23. If instead the cells were pre-treated with PNAEmwt tumor growth was observed at later times (not detectable at day 19 from inoculum when the two control tumors were already palpable). The average mass7s.e.m. (of the six mice per experiment in triplicate experiments) at each time point was consistently about a quarter of that observed in SCID mice inoculated with BRG cells untreated or pre-treated with PNAEmmut (1572% at day 23; 2873% at day 25; 2273% at day 30), with a Po 0.001 (Figure 1a, top  panel) .
In parallel identically designed experiment, Ramos cells were used to induce tumors in SCID mice. However, the tumors derived from these BL had identical growth curve irrespectively of the type of PNA treatment in vivo (Figure 1a, bottom panel) .
Cells from tumors generated by inoculum of BRG cells following pre-treatment both with PNAEmwt or with PNAEmmut had virtually identical flow cytometry patterns when stained for BL cell markers (CD19, m chain, k and l light chains) indicating that all the tumors were indeed constituted by BRG-BL cells (Figure 1b ). 9 This pattern is characterized by a monomorphic carpet of medium-size lymphoid cells with round, non-cleaved nuclei, clumped chromatin, several basophilic nucleoli and an appreciable rim of basophilic cytoplasm. Numerous mitoses were also evident. Cellular proliferation was associated with some necrosis as documented by pyknotic nuclei and nuclear fragments scattered throughout the tumor. Irregularly shaped macrophages, exhibiting engulfed pyknotic nuclei and cell debris (tingible-body macrophages), were also present. 9 By immunohistochemical staining and evaluation of these tumors sections (top right corner insert in both panel of Figure 1c ) MYC signal appeared to be present in all tumors at the same level and with the same localization irrespectively from the type of in vitro treatment before inoculum.
Likewise cells from tumors originated either by PNAEmwt pre-treated or matching control cells gave virtually identical patterns when analyzed for MYC expression by flow cytometry (Figure 1b) . Moreover in PNAEmwt-treated cells c-myc mRNA was decreased by 64% as observed by Northern blot before inoculum (Figure 1d) .
However c-myc mRNA was back to the values observed in the control cells in those cells that were able to grow in SCID mice (Figure 1e ). Finally, in line with these findings, MYC and m chain expression in the tumors generated in PNAEmwt or PNAEmmut pretreated cells was not different as observed by Western blot (Figure 1f) .
Taken together these findings demonstrate that the cells able to grow in SCID mice could escape the inhibitory effect of PNAEmwt and their capacity of expressing both genes under Em control was unaltered. Reduction of tumor size by PNAEmwt injection in tumor-bearing mice Subsequently, we tested whether PNAEmwt administration to SCID mice after inoculum of BRG cells could block tumor growth.
Eighteen SCID mice were inoculated s.c. with 1.5 Â 10 6 BRG cells. One group of six mice was left untreated throughout the experiment (control 1) while the other two groups of six mice were treated with every other day i.v. injections of PNAEmmut (control 2) or PNAEmwt. These treatments were started 10 days after the cell inoculum. In the two control groups, tumors were detectable at day 16 after inoculum while in the PNAEmwt-treated mice tumors were palpable at day 20 only. The growth trend of tumors in the two control (1 and 2) sets of mice was very similar as assessed by calculating average mass7 s.e.m. as described above. In these mice tumors continued to linearly increase till the end of the experiment (30 days). In contrast after eight injections of PNAEmwt (around the day 26) the tumor volume started to plateau. In PNAEmwt-treated mice groups the tumor mass was consistently in the range of a quarter of the controls (2673% at day 20; 2773% at day 22; 2773% at day 24; 2873% at day 26; 2673% at day 28; 24.673% at day 30) with a Po0.001 (Figure 2a) . The graphs in Figure 2a show the results of one typical test out of three.
Tumor cells removed from both test and control mice were characterized for a number of parameters.
Cells from all mice groups expressed CD19, IgM and l on their surface and also had intracytoplasmatic m and l indicating their origin from the inoculated BRG-BL cells (Figure 2b ). The intensity of fluorescence for m and l chains was lower in the cells from PNAEmwt-treated mice (Figure 2b ). This finding also was confirmed by Western blot analysis (Figure 2c ). The decrease, calculated by Western blot, was of 7276% and 5375% for IgM and MYC, respectively.
The histology of tumor of PNAEmwt-treated mice (Figure 2e) showed a pattern similar to tumors from PNAEmmut-treated mice (Figure 2d) . A major difference however was that this pattern was now interspersed by diffuse areas of coagulative necrosis (about 8% of the neoplastic cells) (Figure 2e ). At the external boundary of these necrotic areas tumor cells displayed nuclear changes, including nuclear shrinkage and increased basophilia, associated with karyorrhexis detectable at high magnification (Figure 2f) . Furthermore toward the center of these necrotic areas the predominant features were abnormal nuclei intermingled with coagulated nonnucleated eosinophilic cells.
By immunohistochemical analysis of similar tumor sections the signal intensity and distribution of MYC from PNAEmwt (Figure 2h and i) and PNAEmmuttreated mice (Figure 2g ) differed substantially. Infact, while in control tumors MYC maintained an homogeneous distribution (Figure 2g ), in tumor PNAEmwttreated mice MYC signal exhibited an apparent gradual decrease from the outer toward the inner portion of the necrotic area, although maintaining the same cytoplasmic and perinuclear localization (Figure 2h and i) .
Discussion
In the recent years, considerable evidence demonstrated that appropriately designed PNAs are capable of entering the cell nuclei, of invading complementary DNA strands and of eventually causing the inhibition of the targeted gene transcription. Therefore, PNAs not only appear to be ideal reagents to determine gene function in cultured cells in vitro but also their use in vivo may open new avenues for more specific therapeutical approaches to neoplasia.
In the past, we investigated the feasibility of inhibiting BL cell growth in vitro with appropriately designed PNAs. The BL model system was initially selected because of the evidence that the cell malignant condition was primarily dependent upon a single oncogene, that is the c-myc, which is translocated and upregulated in BL. c-myc encodes a transcription factor, which facilitates the cell entrance into the G1 phase of cell cycle. Thus, transfection of normal cells with vectors carrying an overexpressed c-myc induces the appearance of most phenotypic and functional features characteristic of BL cells. 8, 10 Moreover, mice made transgenic for c-myc, under the control of the same promoter(s) used by the translocated c-myc in BL, develop lymphomatous lesions in relatively short time. 10 Therefore, based upon these considerations, it could be predicted that a specific block of the translocated c-myc in vitro, would result in the loss of a number if not of all the malignant properties by BL cells. Indeed, this has proven to be the case when BL cells were treated with the appropriate PNAs specific for c-myc oncogene in vitro.
2,4 A proliferation arrest was observed in these cells, 4 many of which initiated a process of differentiation towards Ig secreting plasma-cells before undergoing death by necrosis (unpublished results).
Kinetics studies on PNAs in mice demonstrated that PNAs could remain intact in vivo for prolonged time. 5 Moreover, PNAs, when appropriately designed, were concentrated particularly in BL tumor masses in SCID mice inoculated with BL cells. 5 Based on these and above considerations, we have undertaken this preliminary study to ascertain whether PNAs could represent suitable agents to attempt a 'cure' for human BL cells growing in SCID mice. Two lines of evidence demonstrate the potential capacity of PNAs to specifically and selectively block BL cells expansion.
BL cells treated with PNAEmwt before the inoculum into SCID mice grew more slowly and yielded smaller tumor masses than BL cells treated with PNAEmmut ( Figure 1a) . However, tumors derived from cells pretreated with PNAEmwt retained the same Ig markers as the inoculum cells (Figure 1b) , the same MYC (Figure 1e and f) and IgM ( Figure 1f ) the expression level and the same MYC localization than control tumor cells (Figure 1c ). All these results support the hypothesis that tumors from PNAEmwt pre-treated BRG-BL cells derive from a cell population unaffected by the initial in vitro PNAEmwt pre-treatment.
Chronic multiple i.v. administrations of PNAEmwt in vivo, to mice already inoculated with tumors cells, inhibited significantly both the size and the time of appearance of tumors. Analysis of final tumor demonstrated that tumor cells from mice chronically treated with PNAEmwt retained the same markers, detectable by flow cytometry, than the originally grafted cells (Figure 2b) . However, the level of IgM and c-myc was downregulated when compared to that of control tumor cells either by flow cytometric (Figure 2b) or by Western blot analysis (Figure 2c ) or by immunohistochemistry (Figure 2h and i). Tumor sections exhibited significant loss of the c-myc signal particularly in the cells located in proximity of the necrotic areas (Figure 2h and i) . These data suggest that, with the present administration regimen, only a portion of the neoplastic cells growing in vivo has the chance to absorb and therefore, to be affected by PNAEmwt. These observations leave room for improvement of the antineoplastic efficacy of PNAEmwt probably through a shift to a continuous administration of PNA. Irrespective of the improvements that can be achieved, it is of note that PNAEmwt consistently displayed a selective inhibition of c-myc, as documented by the specific inhibition of the growth of BRG cells with the 'correct' geometry of c-myc translocation. Both set of experiments -those where BL cells were pre-treated with PNAs in vitro before inoculum and -those where BL inoculated mice were treated with PNAs in vivo, the extent of growth inhibition of the malignant cells represents a remarkable achievement, especially considering the fast growth rate of BL cells caused by translocation and consequent upregulation of c-myc.
Notably, the histology of tumor masses in PNAEmwttreated animals revealed consistent tissue necrosis, which was more prominent around the vascular component of the tumors. This perhaps indicates that PNAs were primarily adsorbed by cells in closer contact with the vascular endothelium and suggests various procedures that could improve the final results. These procedures include attempts to enhance permeability of the vascular endothelium as well as the concomitant increase in PNAs availability in vivo through a continuous instead of discontinuous administration.
Necrosis was the major event observed in the treated tumors. Although the definition of cell death mode induced by PNA treatment goes beyond the aims of the present study, it is perhaps important to point out that necrosis is the predominant death type observed in the BL cells exposed to PNAEmwt. In vitro 4 apoptosis (a c-mycdependent process) is impaired in the PNAEmwt-treated cells that consequently undergo a necrosis type of death. 10 In summary, the data presented here provide an exciting advance towards the pre-clinical application of PNAs in the treatment of BL. These advances are not only of relevance for BL, but also for other lymphomas, the genesis of which is largely dependent upon the translocation of certain oncogenes posed directly under the control of the Em enhancer element.
